Redmile Group, LLC - 02 Nov 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
10%+ Owner
Signature
/s/ Jeremy Green, Managing Member of Redmile Group, LLC
Issuer symbol
TRDA
Transactions as of
02 Nov 2021
Net transactions value
+$20,000,000
Form type
4
Filing time
04 Nov 2021, 21:00:33 UTC
Previous filing
21 Apr 2023
Next filing
04 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Conversion of derivative security +954,420 954,420 02 Nov 2021 See Footnote F1, F2
transaction TRDA Common Stock Purchase $20,000,000 +1,000,000 +105% $20.00 1,954,420 02 Nov 2021 See Footnote F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Series B Convertible Preferred Stock Conversion of derivative security $0 -954,420 -100% $0.000000* 0 02 Nov 2021 Common Stock 954,420 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Redmile Group, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.
F2 These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3 Reflects number of shares owned as of November 2, 2021.